TNP-470/minocycline/cytotoxic therapy: A systems approach to cancer therapy

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2461-2466

  Teicher, B A ^a   Emi, Y ^a   Kakeji, Y ^a   Northey, D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; MINOCYCLINE;

ANIMAL EXPERIMENT; CANCER RADIOTHERAPY; CANCER THERAPY; CYTOTOXICITY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030498702     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00380-2     Document Type: Article

References (52)

1. 1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, March 23, 571-573.
2. 2. Poste G, Paruch L, Paget S. A retrospective. Cancer Metastasis Rev 1989, 8, 93-97.
3. 3. Marcel MM, Van Roy FM, Bracke ME. How and when do tumour cells metastasize? Crit Rev Oncogenesis 1993, 4, 559-594.
4. 4. Kohn EC. Development and prevention of metastasis. Anticancer Res 1993, 13, 2553-2560.
5. 5. Freitas I, Baronzio GF. Neglected factors in cancer treatment: cellular interactions and dynamic microenvironment in solid tumors. Anticancer Res 1994, 14, 1097-1102.
6. 6. Wellstein A. Growth factor targeted and conventional therapy of breast cancer. Breast Cancer Res Treat 1994, 31, 141-152.
7. 7. Connolly JL, Ducatman BS, Schnitt SJ, Dvorak AM, Dvorak HF. Principles of cancer pathology. In Holland JF, Frei III E, Bast Jr RC, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer Medicine 1. Philadelphia, PA, Lea & Febiger, 1993, 432-450.
8. 8. Cotran RS, Kumar V, Robbins SL. Neoplasia. Philadelphia, PA, W.B. Saunders Co., 1989.
9. 9. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315, 1650-1659.
10. 10. Nagy JA, Brown LF, Senger DR, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989, 948, 305-326.
11. 11. Killough JH, Magill GB, Smith RC. The treatment of amebiasis with fumagillin. Science 1952, 115, 71-72.
12. 12. Katznelson H, Jamieson CA. Control of nosema disease of honeybees with fumagillm. Science 1952, 115, 70-71.
13. 13. Brem H, Ingber D, Blood CH, Bradley D, Urioste S, Folkman J. Suppression of tumor metastasis by angiogenesis inhibition. Surgical Forum 1991, 42, 439-441.
14. 14. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348, 555-557.
15. 15. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 1991, 174, 1070-1076.
16. 16. Brem H, Folkman J. Analysis of experimental antiangiogenic therapy. Pediatric Surg 1993, 28, 445-451.
17. 17. Takayamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL. Inhibition of angiogenesis and growth of human nerve sheath tumors by AGM-1470. J Neurosurg 1993, 78, 470-476.
18. 18. Brem H, Gresser I, Grossfeld J, Folkman J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatric Surg 1993, 28, 445-451.
19. 19. Kamei S, Okada H, Inoue Y, Yoshioka T, Ogawa Y, Toguchi H. Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J Pharmacol Exp Therap 1993, 264, 469-474.
20. 20. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T. Inhibition of tumor growth and metastasis of rodent tumours by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillin (TNP-470; AGM-1470). Cancer Res 1993, 53, 4262-4267.
21. 21. Toi M, Yamamoto Y, Imazawa T, Takayanagi T, Akutsu K, Tominaga T. Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. Int J Oncol 1993, 3, 525-528.
22. 22. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993, 53, 5233-5236.
23. 23. Schoof DD, Obando JA, Cusack Jr JC, Goedegebuure PS, Brem H, Eberlein TJ. The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro. Int J Cancer 1993, 55, 630-635.
24. 24. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. Cancer Res 1993, 53, 2566-2570.
25. 25. Golub LM, Lee HM, Nemiroff LA, McNamara TF, Kaplan R, Ramamurthy NS. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983, 18, 516-526.
26. 26. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dental Res 1987, 66, 1310-1314.
27. 27. Greenwald RA, Golub LM, Lavietes B, et al. Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol 1987, 14, 28-32.
28. 28. Zucker S, Lysik RM, Ramamurthy S, Golub LM, Wieman JM, Wilkie DP. Diversity of melanoma plasma membrane proteinase: inhibition of collagenolytic and cytolytic activities by minocycline. J Natl Cancer Inst 1985, 75, 517-525.
29. 29. Tilley BC, Alarcón GS, Heyse SP, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Int Med 1995, 122, 81-89.
30. 30. Golub LM, Ramamurthy NS, McNamara TF, Grenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991, 2, 297-321.
31. 31. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991, 51, 672-675.
32. 32. Riess JG. Reassessment of criteria for the selection of perfluorochemicals for second-generation blood substitutes: analysis of structure/property relationships. Artif Organs 1984, 8, 44-56.
33. 33. Alvarez Sotomayor E, Teicher BA, et al. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol 1992, 30, 377-384.
34. 34. Teicher BA, Alvarez Sotomayor E, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992, 52, 6702-6704.
35. 35. Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer 1994, 57, 920-925.
36. 36. Teicher BA, Dupuis N, Kusumoto T, et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 1995, 2, 269-276.
37. 37. Teicher B, Holden S, Ara G, Korbut T, Menon K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in Lewis lung carcinoma. Cancer Chemother Pharmacol 1996, 38, 169-177.
38. 38. Teicher BA, Herman TS, Holden SA, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990, 247, 1457-1461.
39. 39. Teicher BA, Chatterjee D, Liu J-T, Holden SA, Ara G. Protection of bone marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors. Cancer Chemother Pharmacol 1993, 32, 315-319.
40. 40. Teicher BA, Holden SA, Dupuis NP, et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 1995, 36, 227-236.
41. 41. Teicher BA, Holden SA, Menon K, Hopkins RE, Gawryl MS. Effect of a hemoglobin solution on the response of intracranial and subcutaneous 9L tumors to antitumor alkylating agents. Cancer Chemother Pharmacol 1993, 33, 57-62.
42. 42. Teicher BA, Holden SA, Ara G, et al. Influence of an antiangiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer 1995, 61, 732-737.
43. 43. Summerhayes IC, Lampidis TJ, Bernal SD, et al. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Natl Acad Sci USA 1982, 79, 5292-5296.
44. 44. Frei III E, Teicher BA, Holden SA, Cathcart KNS, Wang Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988, 48, 6417-6423.
45. 45. Saijo Y, Perlaky L, Valdez BC, et al. The effect of antisense p 120 construct on p 120 expression and cell proliferation in human breast cancer MCF-7 cells. Cancer Lett 1993, 68, 95-104.
46. 46. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992, 24, 85-95.
47. 47. Teicher BA, Alvarez Sotomayor E, Robinson MF, Dupuis NP, Schwartz GN, Frei III E. Tumor oxygenation and radiosensitization by pentoxifylline and a perflubron emulsion/carbogen breathing. Int J Oncol 1993, 2, 13-21.
48. 48. Teicher BA, Dupuis NP, Holden SA, Schwartz GN, Lester S, Frei III E. Definition and manipulation of tumor oxygenation. Radiat Oncol Invest 1994, 2, 66-76.
49. 49. Teicher BA, Dupuis NP, Robinson M, Emi Y, Goff D. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res 1995, 7, 237-243.
50. 3 cell adhesion, motility, and liver metastasis of murine RAW117 large cell lymphoma. Cancer Res 1996, 56, 3103-3111.
51. 51. Maher J, Bissell D. Cell-matrix interactions in liver. Cell Biol 1993, 4, 189-201.
52. 52. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995, 13, 765-782.